In studies conducted in patients with active rheumatoid arthritis, peripheral blood CD4+CD25+ Tregs have shown reduced FOXP3 expression and suppressive function which can be reversed by treatment with an anti-TNFα monoclonal antibody (infliximab) [19, 20]. This evidence concerns the gene TNF and rheumatoid arthritis.